Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Buerger, K. Articles by Hampel, H. Search for Related Content PubMed Citation Articles by Buerger, K. Articles by Hampel, H. Neurophysiology Geriatric Psychiatry Depression Alzheimer's Disease

Differentiation of Geriatric Major Depression From Alzheimer’s Disease With CSF Tau Protein Phosphorylated at Threonine 231

OBJECTIVE: Differentiation of geriatric major depression from Alzheimer’s disease is hampered by overlapping symptoms. Increased CSF concentrations of tau protein phosphorylated at threonine 231 (p-tau₂₃₁) have been suggested as a biomarker for Alzheimer’s disease. The authors asked whether p-tau₂₃₁ levels improve the differential diagnosis between geriatric major depression and Alzheimer’s disease. METHOD: Included were 34 depression subjects, 64 with probable Alzheimer’s disease, 17 with possible Alzheimer’s disease, and 21 healthy comparison subjects. P-tau₂₃₁ concentrations were measured with an enzyme-linked immunosorbent assay. RESULTS: P-tau₂₃₁ levels were significantly higher in Alzheimer’s disease than in geriatric major depression patients and healthy comparison subjects. For differentiation of probable Alzheimer’s disease from major depression, p-tau₂₃₁ correctly allocated 87% of subjects. When possible mild Alzheimer’s disease was compared to major depression, p-tau₂₃₁ correctly allocated 78% of subjects. CONCLUSIONS: CSF p-tau₂₃₁ should be evaluated as a potential biological marker for differentiation of geriatric depression from Alzheimer’s disease.

This article has been cited by other articles:

				A J Mitchell CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies J. Neurol. Neurosurg. Psychiatry, September 1, 2009; 80(9): 966 - 975. [Abstract] [Full Text] [PDF]

				A. Pfennig, E. Littmann, and M. Bauer Neurocognitive Impairment and Dementia in Mood Disorders J Neuropsychiatry Clin Neurosci, November 1, 2007; 19(4): 373 - 382. [Abstract] [Full Text] [PDF]

				K. Buerger, M. Ewers, T. Pirttila, R. Zinkowski, I. Alafuzoff, S. J. Teipel, J. DeBernardis, D. Kerkman, C. McCulloch, H. Soininen, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain, November 1, 2006; 129(11): 3035 - 3041. [Abstract] [Full Text] [PDF]

				N. S.M. Schoonenboom, Y. A.L. Pijnenburg, C. Mulder, S. M. Rosso, E. -J. Van Elk, G. J. Van Kamp, J. C. Van Swieten, and Ph. Scheltens Amyloid {beta}(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease Neurology, May 11, 2004; 62(9): 1580 - 1584. [Abstract] [Full Text] [PDF]

				H. Hampel, K. Buerger, R. Zinkowski, S. J. Teipel, A. Goernitz, N. Andreasen, M. Sjoegren, J. DeBernardis, D. Kerkman, K. Ishiguro, et al. Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study Arch Gen Psychiatry, January 1, 2004; 61(1): 95 - 102. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us